Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women

BACKGROUND: In the HIV-1 vaccine trial RV144, ALVAC-HIV prime with an AIDSVAX(®) B/E boost reduced HIV-1 acquisition by 31% at 42 months post first vaccination. The bivalent AIDSVAX(®) B/E vaccine contains two gp120 envelope glycoproteins, one from the subtype B HIV-1 MN isolate and one from the sub...

Descripción completa

Detalles Bibliográficos
Autores principales: Gilbert, Peter B., Excler, Jean-Louis, Tomaras, Georgia D., Carpp, Lindsay N., Haynes, Barton F., Liao, Hua-Xin, Montefiori, David C., Rerks-Ngarm, Supachai, Pitisuttithum, Punnee, Nitayaphan, Sorachai, Kaewkungwal, Jaranit, Kijak, Gustavo H., Tovanabutra, Sodsai, Francis, Donald P., Lee, Carter, Sinangil, Faruk, Berman, Phillip W., Premsri, Nakorn, Kunasol, Prayura, O’Connell, Robert J., Michael, Nelson L., Robb, Merlin L., Morrow, Rhoda, Corey, Lawrence, Kim, Jerome H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5426618/
https://www.ncbi.nlm.nih.gov/pubmed/28493891
http://dx.doi.org/10.1371/journal.pone.0176428

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5426618/
https://www.ncbi.nlm.nih.gov/pubmed/28493891
http://dx.doi.org/10.1371/journal.pone.0176428

Ejemplares similares